文献速递临床试验与 GCP

当归须散治疗急性外侧踝关节扭伤的随机对照试验方案

Effects of Dangguixu-san on acute lateral ankle sprain: study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2018-03-27

本研究为随机、双盲、安慰剂对照、平行组临床试验方案,拟纳入48例72小时内发生的急性外侧踝关节扭伤患者,按1:1随机分配至当归须散组(n=24)或安慰剂组(n=24)。两组均接受每日一次、每周5天的针刺治疗,并服用试验药物(当归须散/安慰剂胶囊)每日三次、连续7天。主要结局为视觉模拟量表(VAS)评估的疼痛缓解,次要结局包括足踝结局评分(FAOS)、水肿、EQ-5D-5L评分及踝关节扭伤复发次数。

要点

  • 当归须散组与安慰剂组各24例,均联合针刺治疗。
  • 主要结局为VAS疼痛评分,次要结局含FAOS、水肿、EQ-5D-5L及复发次数。
  • VAS、FAOS、水肿和EQ-5D-5L在治疗前、治疗结束时及治疗后4周记录。

核心结论

  • 本试验旨在评估当归须散治疗急性外侧踝关节扭伤的有效性和安全性。

研究设计与样本

  • 随机、双盲、安慰剂对照、平行组临床试验,1:1分配,共纳入48例急性外侧踝关节扭伤患者。
  • 纳入标准为入组前72小时内发生的急性外侧踝关节扭伤,当归须散组24例,安慰剂组24例。
  • 两组均每日针刺一次、每周5天(周六周日除外),并服用试验药物每日三次、连续7天。

关键数值与推荐

  • 主要结局为VAS评估的疼痛缓解。
  • 次要结局包括FAOS、水肿、EQ-5D-5L评分及踝关节扭伤复发次数。
  • VAS、FAOS、水肿和EQ-5D-5L在治疗前、治疗结束时及治疗后4周记录;EQ-5D-5L额外在治疗后26周记录。
  • 踝关节扭伤复发次数在治疗后4、8、12和26周记录。

临床怎么用

  • 本方案为后续当归须散用于急性外侧踝关节扭伤的疗效与安全性评价提供依据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Ankle sprain is a common musculoskeletal injury. In Korean medicine, blood stasis is thought to be the main cause of pain and swelling in patients with ankle sprain. Dangguixu-san (DS), a herbal extract, is widely used in Korean medicine for the treatment of traumatic ecchymosis and pain by promoting blood circulation and relieving blood stasis. However, the effects of DS on ankle sprain have not been evaluated in a randomized clinical trial. Here, we describe the protocol for a randomized controlled trial that will evaluate the efficacy and safety of DS for the treatment of ankle sprain. METHODS/DESIGN: In this randomized, double-blinded, placebo-controlled, parallel-arm clinical trial with a 1:1 allocation ratio, participants (n = 48) with acute lateral ankle sprain (ALAS) that occurred within 72 h before enrollment will be randomly assigned to a DS (n = 24) or a placebo (n = 24) group. Both groups will receive acupuncture treatment once a day for 5 days a week (excluding Saturday and Sunday) and the trial medication (DS/placebo capsule) three times a day for seven consecutive days. The primary outcome measure will be pain relief evaluated using a Visual Analog Scale (VAS). Secondary outcome measures will include Foot and Ankle Outcome Scores (FAOS), edema, European Quality of Life Five-Dimension-Five-Level Scale (EQ-5D-5 L) scores, and the number of recurrent ankle sprains. VAS, FAOS, edema, and EQ-5D-5 L scores will be recorded before, at the end of, and at 4 weeks after treatment completion. EQ-5D-5 L scores will be additionally recorded at 26 weeks after treatment completion. The number of recurrent ankle sprains will be recorded at 4, 8, 12, and 26 weeks after treatment completion. DISCUSSION: This study is expected to provide evidence regarding the efficacy, safety, and usefulness of DS for the treatment of ALAS. TRIAL REGISTRATION: cris.nih.go.kr, registration number: KCT 0002374 . Registered on 11 July, 2017 and approved by the Ministry of Food and Drug Safety (registration number, 31244).

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Kim JH, Lee EY, Cho MR, et al. Effects of Dangguixu-san on acute lateral ankle sprain: study protocol for a randomized controlled trial. Trials. 2018. PMID: 29587801. doi:10.1186/s13063-018-2571-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。